The fourth United Nations Millennium Development Goal, adopted in 2000, set a target
to reduce child mortality by two thirds by 2015. One indicator of progress toward
this target was measles vaccination coverage (
1
). In 2010, the World Health Assembly (WHA) set three milestones for measles control
by 2015: 1) increase routine coverage with the first dose of a measles-containing
vaccine (MCV1) among children aged 1 year to ≥90% at the national level and to ≥80%
in every district; 2) reduce global annual measles incidence to <5 cases per million
population; and 3) reduce global measles mortality by 95% from the 2000 estimate (
2
).* In 2012, WHA endorsed the Global Vaccine Action Plan,
†
with the objective of eliminating measles in four World Health Organization (WHO)
regions by 2015 and in five regions by 2020. Countries in all six WHO regions have
adopted goals for measles elimination by or before 2020. Measles elimination is defined
as the absence of endemic measles virus transmission in a region or other defined
geographic area for ≥12 months, in the presence of a high quality surveillance system
that meets targets of key performance indicators. This report updates a previous report
(
3
) and describes progress toward global measles control milestones and regional measles
elimination goals during 2000–2016. During this period, annual reported measles incidence
decreased 87%, from 145 to 19 cases per million persons, and annual estimated measles
deaths decreased 84%, from 550,100 to 89,780; measles vaccination prevented an estimated
20.4 million deaths. However, the 2015 milestones have not yet been met; only one
WHO region has been verified as having eliminated measles. Improved implementation
of elimination strategies by countries and their partners is needed, with focus on
increasing vaccination coverage through substantial and sustained additional investments
in health systems, strengthening surveillance systems, using surveillance data to
drive programmatic actions, securing political commitment, and raising the visibility
of measles elimination goals.
Immunization Activities
To estimate coverage with MCV1 and the second dose of measles-containing vaccine (MCV2)
through routine immunization services,
§
WHO and the United Nations Children’s Fund (UNICEF) use data from administrative records
(administrative coverage is calculated by dividing the vaccine doses administered
by the estimated target population) and immunization coverage surveys reported annually
by 194 countries. During 2000–2016, estimated MCV1 coverage increased globally from
72% to 85% (Table 1), although coverage has not increased since 2009. Considerable
variability in regional coverage exists. Since 2012, MCV1 coverage has remained essentially
unchanged in the African Region (AFR) (72%), the Region of the Americas (AMR) (92%),
and the Eastern Mediterranean Region (EMR) (77%). In the European Region (EUR), MCV1
coverage has declined from 95% to 93% since 2012, with 51% of EUR member states reporting
lower coverage since 2013. In the South-East Asia Region (SEAR), MCV1 coverage increased
slightly since 2012, from 84% to 87%. The Western Pacific Region (WPR) is the only
region that has achieved and sustained MCV1 coverage >95% (since 2008). Since 2000,
the number of countries with MCV1 coverage of ≥90% increased globally from 85 (44%)
in 2000 to 119 (61%) in 2015, and to 123 (63%) in 2016. However, among countries with
≥90% MCV1 coverage nationally, the percentage with ≥80% MCV1 coverage in all districts
declined from 46% (52 of 112) in 2010 to 45% (49 of 110) in 2015 and 36% (44 of 123)
in 2016. Among the estimated 20.8 million infants who did not receive MCV1 through
routine immunization services in 2016, approximately 11 million (53%) were in six
countries with large birth cohorts and suboptimal coverage: Nigeria (3.3 million),
India (2.9 million), Pakistan (2.0 million), Indonesia (1.2 million), Ethiopia (0.9
million), and the Democratic Republic of the Congo (0.7 million).
TABLE 1
Estimates of coverage with the first and second doses of measles-containing vaccine
administered through routine immunization services, reported measles cases and incidence,
and estimated measles deaths,* by World Health Organization (WHO) region — worldwide,
2000 and 2016
WHO region (no. countries in region)/Year
% Coverage with MCV1†
% Countries with ≥90% MCV1 coverage
% Coverage with MCV2†
% Countries with incidence <5/million
No. reported measles cases§
Measles incidence§,¶
Estimated no. of measles deaths (95% CI)
% Estimated mortality reduction, 2000–2016
African (47)
2000
53
9
5
8
520,102
835
340,800 (232,000–554,000)
89
2016
72
36
24
51
36,269
36
37,500 (11,900–124,200)
Americas (35)
2000
93
63
43
89
1,754
2.1
NA
—
2016
92
74
54
100
12
0.02
NA
Eastern Mediterranean (21)
2000
72
57
29
17
38,592
90
55,300 (35,000–87,700)
79
2016
77
57
69
47
6,264
10
11,400 (5,700–28,300)
European (53)
2000
91
60
48
45
37,421
50
400 (130–2,000)
80
2016
93
83
88
85
4,175
5
80 (0–1,400)
South-East Asia (11)
2000
63
30
3
0
78,558
51
143,000 (101,500–199,900)
73
2016
87
64
75
27
27,530
14
39,000 (27,600–69,700)
Western Pacific (27)
2000
85
48
2
30
177,052
105
10,600 (5,200–52,400)
83
2016
96
63
93
67
57,879
31
1,800 (500–46,000)
Total (194)
2000
72
44
15
38
853,479
145
550,100 (374,000–896,500)
84
2016
85
63
64
69
132,137
19
89,780 (45,700–269,600)
Abbreviations: CI = confidence interval; MCV1 = first dose of measles-containing vaccine;
MCV2 = second dose of measles-containing vaccine; NA = not applicable; UNICEF = United
Nations Children’s Fund.
* Mortality estimates for 2000 might be different from previous reports. When the
model used to generate estimated measles deaths is rerun each year using the new WHO/UNICEF
Estimates of National Immunization Coverage data, as well as updated surveillance
data, adjusted results for each year, including the baseline year, are also produced
and updated.
† Coverage data: WHO/UNICEF Estimates of National Immunization Coverage, July 15,
2017 update. http://www.who.int/immunization/monitoring_surveillance/data/en.
§ Reported case data: measles cases (2016) from World Health Organization, as of July
15, 2017 (http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencemeasles.html).
Reported cases are a sizeable underestimate of the actual number of cases, accounting
for the inconsistency between reported cases and estimated deaths.
¶ Cases per 1 million population; population data from United Nations, Department
of Economic and Social Affairs, Population Division, 2016. Any country not reporting
data on measles cases for that year was removed from both the numerator and denominator.
During 2000–2016, the number of countries providing MCV2 nationally through routine
services increased from 98 (51%) to 164 (85%), with four countries (Guatemala, Haiti,
Papua New Guinea, and Timor-Leste) introducing MCV2 in 2016. Estimated global MCV2
coverage steadily increased from 15% in 2000 to 60% in 2015 and 64% in 2016 (Table
1). During 2016, approximately 119 million persons received supplementary doses of
measles-containing vaccine (MCV) during 33 mass immunization campaigns, known as supplementary
immunization activities (SIAs),
¶
implemented in 31 countries (Table 2). Based on doses administered, SIA coverage was
≥95% in 20 (61%) SIAs. Among the six countries that conducted post-SIA coverage surveys,
estimated coverage was ≥95% in three, 90%–94% in two, and 84% in one.
TABLE 2
Measles supplementary immunization activities (SIAs)* and the delivery of other child
health interventions, by World Health Organization (WHO) region and country — worldwide,
2016
WHO region/country
Age group targeted
Extent of SIA
No. children reached in targeted age group (%)†
% coverage based on survey results
Other interventions delivered
African
Botswana
9 mos–14 yrs
N
674,150 (95)
97
Rubella vaccine
Burundi (2015–2016)§
18–23 mos
N
30,443 (22)
—
—
Central African Republic (2015–2016)§
6 mos–10 yrs
N
1,529,441 (84)
—
Vitamin A, deworming
Chad
9–59 mos
N
2,756,733 (110)
—
—
Comoros
9–59 mos
SN
83,371 (76)
—
Vitamin A, deworming
Democratic Republic of the Congo
6–59 mos
N
10,921,820 (100)
—
—
Equatorial Guinea
6–59 mos
N
127,874 (85)
—
—
Ethiopia
6 mos–15 yrs
SN
24,986,589 (97)
94
—
Gambia
9 mos–14 yrs
N
779,654 (97)
97
Rubella vaccine, vitamin A, deworming
Guinea
9–59 mos
N
2,412,923 (103)
—
Vitamin A, deworming
Kenya
9 mos–14 yrs
N
19,154,577 (101)
95
Rubella vaccine
Madagascar
9–59 mos
N
3,547,466 (96)
—
Vitamin A, deworming
Namibia
9 mos–39 yrs
N
1,908,193 (103)
—
Rubella vaccine
Nigeria
9–59 mos
N
19,065,787 (131)
84
—
Sao Tome and Principe
9 mos–14 yrs
N
77,285 (107)
—
Rubella vaccine
Swaziland
9 mos–14 yrs
N
373,508 (90)
94
Rubella vaccine, vitamin A, deworming
Zambia
9 mos–14 yrs
N
7,741,505 (108)
—
Rubella vaccine
Americas
Haiti
9–59 mos
N
1,420,220 (100)
—
Rubella vaccine, OPV, IPV, vitamin A
Honduras
1–4 yrs
N
735,066 (96)
—
Mumps and rubella vaccine
Mexico
1–4 yrs
N
8,229,851 (94)
—
Mumps and rubella vaccine
Nicaragua
1–4 yrs
N
568,422 (105)
—
Mumps and rubella vaccine
Peru
2–5 yrs
N
1,662,728 (78)
—
Rubella vaccine
Eastern Mediterranean
Egypt
11–20 yrs
SN
642,178 (94)
—
Rubella vaccine
Egypt
6–7 yrs (1st grade)
SN
258,464 (102)
—
Rubella vaccine
Qatar
1–13 yrs
N
166,145 (87)
—
Mumps and rubella vaccine
South-East Asia
Bangladesh
9–59 mos
SN
100,863 (101)
—
Rubella vaccine
Indonesia
9–59 mos
SN
3,638,183 (86)
—
Nepal
9–59 mos
N
2,528,539 (101)
—
Rubella vaccine
Western Pacific
Malaysia
6 m–17 yrs
SN
139,382 (85)
—
Rubella vaccine
Malaysia
1–17 yrs
SN
572 (99)
—
Rubella vaccine
Mongolia
18–30 yrs
N
549,846 (88)
—
Rubella vaccine
Papua New Guinea
9 mos–15 yrs
SN
436,854 (63)
—
Rubella vaccine
Vietnam
16–17 yrs
N
1,787,588 (95)
—
Rubella vaccine
Abbreviations: IPV = inactivated polio vaccine; N = National; OPV = oral polio vaccine;
SIA = supplementary immunization activity; SN = subnational.
* SIAs generally are carried out using two approaches: 1) An initial, nationwide catch-up
SIA targets all children aged 9 months to 14 years; it has the goal of eliminating
susceptibility to measles in the general population. Periodic follow-up SIAs then
target all children born since the last SIA. 2) Follow-up SIAs are generally conducted
nationwide every 2–4 years and target children aged 9–59 months; their goal is to
eliminate any measles susceptibility that has developed in recent birth cohorts and
to protect children who did not respond to the first measles vaccination. The exact
age range for follow-up SIAs depends on the age-specific incidence of measles, coverage
with 1 dose of measles-containing vaccine, and the time since the last SIA.
† Values >100% indicate that the intervention reached more persons than the estimated
target population.
§ Rollover national campaigns started the previous year or will continue into the
next year.
Disease Incidence
Countries report the aggregate number of incident measles cases**
,
††
to WHO and UNICEF annually through the Joint Reporting Form. In 2016, 189 (97%) countries
conducted case-based surveillance in at least part of the country, and 191 (98%) had
access to standardized quality-controlled testing through the WHO Global Measles and
Rubella Laboratory Network. Nonetheless, surveillance was weak in many countries;
fewer than half of countries (64 of 134; 48%) achieved the sensitivity indicator target
of two or more discarded measles and rubella
§§
cases per 100,000 population in 2016 compared with 2015 (80 of 135; 59%).
During 2000–2016, the number of measles cases reported annually worldwide decreased
85%, from 853,479 in 2000 to 214,812 in 2015 and then to 132,137 in 2016; measles
incidence decreased 87%, from 145 to 19 cases per 1 million population (Table 1).
Compared with 2015, 2016 incidence decreased from 29 to 19 cases per million, although
three fewer countries (173 of 194; 89%) reported case data in 2016 than did in 2015
(176 of 194; 92%).
¶¶
The percentage of reporting countries with fewer than five measles cases per million
population increased from 38% (64/169) in 2000 to 69% (119/173) in 2016. During 2000–2016,
measles incidence of fewer than five cases per million was sustained in AMR (Table
1).
During 2015–2016, the number of reported measles cases declined globally and in all
regions (AFR, 31%; AMR, 98%; EMR, 71%; EUR, 84%; SEAR, 44%, and WPR, 11%). In addition
to aggregate reporting, countries report measles case-based data to WHO monthly. In
some countries large discrepancies exist between the two reporting systems. During
2016, some countries either did not report or reported only a fraction of monthly
reported measles cases through the Joint Reporting Form (e.g., India reported 70,798
measles cases through monthly reporting, but only 17,250 through the Joint Reporting
Form).
Genotypes of viruses isolated from measles cases were reported by 60 (55%) of the
110 countries that reported at least one measles case in 2016. Among the 24 recognized
measles virus genotypes, 11 were detected during 2005–2008, eight during 2009–2014,
six in 2015, and five in 2016, excluding those from vaccine reactions and cases of
subacute sclerosing panencephalitis, a fatal progressive neurologic disorder caused
by persistent measles infection (
4
).*** In 2016, among 4,796 reported measles virus sequences,
†††
666 were genotype B3 (36 countries); 44 were D4 (four); 1,407 were D8 (43); 87 were
D9 (four); and 2,592 were H1 (13).
Disease and Mortality Estimates
A previously described model for estimating measles disease and mortality was updated
with new measles vaccination coverage data, case data, and United Nations population
estimates for all countries during 2000–2016, enabling derivation of a new series
of disease and mortality estimates (
5
). Based on the updated data, the estimated number of measles cases declined from
29,068,400 (95% confidence interval [CI] = 20,606,800–55,859,000) in 2000 to 6,976,800
(95% CI = 4,190,500–28,657,300) in 2016. During this period, the number of estimated
measles deaths declined 84%, from 550,100 (95% CI = 374,000–896,500) in 2000 to 89,780
(95% CI = 45,700–269,600) in 2016 (Table 1). Compared with no measles vaccination,
measles vaccination prevented an estimated 20.4 million deaths during 2000–2016 (Figure).
FIGURE
Estimated annual number of measles deaths with and without vaccination programs —
worldwide, 2000–2016*
Abbreviation: CL = confidence limit.
* Deaths prevented by vaccination is indicated by the shaded area between estimated
deaths with vaccination and those without vaccination (cumulative total of 20.4 million
deaths prevented during 2000–2016).
The figure above is a line graph showing the estimated annual number of measles deaths
with and without vaccination programs worldwide during 2000–2016.
Regional Verification of Measles Elimination
In 2016, four WHO regions had functioning regional verification commissions. In September
2016, the AMR regional verification commission declared the region free of endemic
measles (
6
). In 2016, the EUR commission verified measles elimination in 24 countries (
7
). Two SEAR countries (Bhutan and Maldives) were verified as having eliminated measles
in 2017 (
8
). The WPR commission reclassified Mongolia as having reestablished endemic measles
virus transmission because of an outbreak that lasted >12 months; thus, five WPR countries
(Australia, Brunei, Cambodia, Japan, and South Korea) and two areas (Macao Special
Autonomous Region [SAR] [China] and Hong Kong SAR [China]) had verified measles elimination
status in 2016 (
9
).
Discussion
During 2000–2016, increased coverage with MCV administered through routine immunization
programs worldwide, combined with SIAs, contributed to an 87% decrease in reported
measles incidence and an 84% reduction in estimated measles mortality. Measles vaccination
prevented an estimated 20.4 million deaths during this period, and during 2016, for
the first time ever, estimated measles deaths declined to fewer than 100,000. Furthermore,
the number of countries with measles incidence of fewer than five per million population
has increased, although considerable underreporting occurred, and AMR has maintained
an incidence of fewer than five cases per million population during 2000–2016. The
decreasing number of circulating measles virus genotypes suggests interruption of
some chains of transmission. However, the 2015 global control milestones were not
met, global MCV1 coverage has stagnated, global MCV2 coverage has reached only 64%,
and SIA quality was inadequate to achieve ≥95% coverage in several countries. With
suboptimal MCV coverage, outbreaks continued to occur among unvaccinated persons,
including school-aged children and young adults.
The 2016 Mid-term Review of the Global Measles and Rubella Strategic Plan 2012–2020
concluded that measles elimination strategies were sound, and the WHO Strategic Advisory
Group of Experts on Immunization endorsed its findings. The review noted, however,
that implementation of the strategies needs improvement. Measures should focus on
strengthening immunization and surveillance systems. The Measles and Rubella Initiative
should increase its emphasis on using surveillance data to drive programmatic actions.
The findings in this report are subject to at least three limitations. First, SIA
coverage data might be biased by inaccurate reports of the number of doses delivered,
doses administered to children outside the target age group, and inaccurate estimates
of the target population size. Second, large differences between the estimated and
reported incidence indicate variable surveillance sensitivity, making comparisons
between countries and regions difficult to interpret. Finally, the accuracy of the
results from the measles mortality model is affected by biases in all model inputs,
including country-specific measles vaccination coverage and measles case-based surveillance
data.
The decrease in measles mortality to fewer than 100,000 deaths in 2016 is one of five
main contributors (along with decreases in mortality from diarrhea, malaria, pneumonia,
and neonatal intrapartum deaths) to the decline in overall child mortality worldwide
and progress toward the fourth United Nations Millennium Development Goal, but continued
work is needed to help achieve measles elimination goals (
10
). Of concern is the possibility that the gains made and future progress in measles
elimination could be reversed when polio-funded resources supporting routine immunization
services, measles SIAs, and measles surveillance diminish and disappear after polio
eradication. Countries with the highest measles mortality rely most heavily on polio-funded
resources and are at highest risk for reversal of progress after polio eradication
is achieved. Improved implementation of elimination strategies by countries and their
partners is needed, with focus on increasing vaccination coverage with substantial
and sustained additional investments in health systems, strengthening surveillance
systems, using surveillance data to drive programmatic actions, securing political
commitment, and raising the visibility of measles elimination goals.
Summary
What is already known about this topic?
The fourth United Nations Millennium Development Goal, adopted in 2000, set a target
to reduce child mortality by two thirds by 2015. One indicator of progress toward
this target was measles vaccination coverage.
What is added by this report?
For the first time, annual estimated measles deaths were fewer than 100,000, in 2016.
This achievement follows an increase in the number of countries providing the second
dose of measles-containing vaccine (MCV2) nationally through routine immunization
services to 164 (85%) of 194 countries, and the vaccination of approximately 119 million
persons against measles during supplementary immunization activities in 2016. During
2000–2016, annual reported measles incidence decreased 87%, from 145 to 19 cases per
million persons, annual estimated measles deaths decreased 84%, from 550,100 to 89,780,
and an estimated 20.4 million deaths were prevented. However, the 2015 measles elimination
milestones have not yet been met, and only one World Health Organization region has
been verified as having eliminated measles.
What are the implications for public health practice?
To achieve measles elimination goals, countries and their partners need to act urgently
to secure political commitment, raise the visibility of measles elimination, increase
vaccination coverage, strengthen surveillance, and mitigate the threat of decreasing
resources once polio eradication is achieved. Polio eradication resources have supported
routine immunization services and surveillance activities.